GCG and diabetes mellitus: Major professional diabetes and cardiac associations have recommended glucose-lowering agents with CV benefits, including sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) agonists, to patients with type 2 DM and established/at risk of ASCVD [76].